Key result
C28, a chemical compound, reversed drug-induced prolongation of cardiac action potentials by selectively facilitating voltage-dependent activation of the IKs potassium channel.
Why the study?
Many approved drugs induce cardiac action potential prolongation that can trigger life-threatening arrhythmias, creating a need for therapies that safely reverse this prolongation.
Does C28 reverse drug-induced action potential prolongation in cardiac cells?
Does C28 reverse drug-induced action potential prolongation in cardiac cells?
The compound C28 reverses drug-induced action potential prolongation by facilitating IKs activation, offering a potential therapeutic strategy for drug-induced arrhythmias.
May counter drug-induced QT prolongation; leaves open clinical translation and safety in humans.
Significance C28, a chemical compound identified by computational screening, selectively facilitates voltage-dependent activation of a cardiac potassium ion channel, I Ks . This compound reverses drug-induced prolongation of the electric signals across the cardiac cell membrane known as action potentials (APs) but minimally affects the normal AP at the same dosage. This outcome supports a computational prediction that enhancing voltage-dependent activation of I Ks could be a potential therapy for AP prolongation. This therapy would increase the safety and expand the therapeutic efficacy of many currently approved drugs that induce AP prolongation, which can trigger life-threatening cardiac arrhythmias.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2021) studied Drug-induced prolongation of action potentials / cardiac arrhythmias. C28 was evaluated on Drug-induced prolongation of action potentials. C28, a chemical compound, reversed drug-induced prolongation of cardiac action potentials by selectively facilitating voltage-dependent activation of the IKs potassium channel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: